Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas.
In August 2018, Congress passed the Foreign Investment Risk Review... Read more »
AstraZeneca has turned to Novoheart’s “human heart-in-a-jar” technology to create a preclinical model that mimics a form of heart failure for which there is no effective therapy available.
Based on Novoheart’s human ventricular cardiac organoid chamber (hvCOC) technology, the companies are... Read more »
La Jolla Pharmaceutical is turning its focus to its lone FDA-approved product and another one in the pipeline after an experimental drug for a rare blood disease failed a late-stage study.
On Monday, La Jolla Pharma (NASDAQ: LJPC) said it... Read more »
Off the heels of a $56 million Series B funding round, Cambridge, UK-headquartered Healx is looking to partner with rare disease patient groups to advance treatments toward the clinic.
The company’s artificial intelligence-powered drug discovery platform, Healnet, uses both public... Read more »
Phoenix Molecular Designs, a biotech developing kinase inhibitors to treat cancer, has brought in an undisclosed amount of financing—boosting its total seed funding raised to $12 million.
The San Diego-based biotech says the proceeds will help fund the Phase 1/1b clinical... Read more »
The FDA on Monday approved a Global Blood Therapeutics treatment for sickle cell disease, three months before the agency’s decision was expected.
Regulators evaluated the drug, voxelotor (Oxbryta), under a pathway that allows for a speedier review using less evidence than... Read more »
Ferring Pharmaceuticals and Blackstone Life Sciences have formed a new company to commercialize a bladder cancer gene therapy that is currently in late-stage clinical testing.
The new company, FerGene, is a subsidiary of Swiss pharmaceutical company Ferring, which is investing $170... Read more »
In startup world these days, the word “biotech” is increasingly accompanied by “computational” and two, two-letter initialisms: AI and ML.
Those tools—artificial intelligence and machine learning, respectively—have been around for decades, but in recent years have become faster and cheaper, accelerating... Read more »
Novartis has agreed to acquire The Medicines Company for $9.7 billion, a cash deal that brings it a compound that is poised to become part of a new wave of cholesterol-lowering drugs.
With the acquisition, Swiss pharma giant Novartis (NYSE: NVS... Read more »